Immutep Advances IMP761 in Promising Phase I Trial

Immutep Ltd (AU:IMM) has released an update.

Immutep Ltd has announced that its Phase I study of IMP761, a novel LAG-3 immunotherapy, has progressed to the dose escalation stage after successful initial trials with no safety issues. This advancement marks a significant step for the biotechnology company in its efforts to develop treatments for cancer and autoimmune diseases. Investors and market watchers are keenly awaiting the safety data expected by the end of the year, which could influence the company’s market position.

For further insights into AU:IMM stock, check out TipRanks’ Stock Analysis page.